260 related articles for article (PubMed ID: 33351131)
1. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
4. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
10. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract][Full Text] [Related]
11. The genomic landscape of core-binding factor acute myeloid leukemias.
Faber ZJ; Chen X; Gedman AL; Boggs K; Cheng J; Ma J; Radtke I; Chao JR; Walsh MP; Song G; Andersson AK; Dang J; Dong L; Liu Y; Huether R; Cai Z; Mulder H; Wu G; Edmonson M; Rusch M; Qu C; Li Y; Vadodaria B; Wang J; Hedlund E; Cao X; Yergeau D; Nakitandwe J; Pounds SB; Shurtleff S; Fulton RS; Fulton LL; Easton J; Parganas E; Pui CH; Rubnitz JE; Ding L; Mardis ER; Wilson RK; Gruber TA; Mullighan CG; Schlenk RF; Paschka P; Döhner K; Döhner H; Bullinger L; Zhang J; Klco JM; Downing JR
Nat Genet; 2016 Dec; 48(12):1551-1556. PubMed ID: 27798625
[TBL] [Abstract][Full Text] [Related]
12. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
[TBL] [Abstract][Full Text] [Related]
13. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
15. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
17. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Itzykson R; Duployez N; Fasan A; Decool G; Marceau-Renaut A; Meggendorfer M; Jourdan E; Petit A; Lapillonne H; Micol JB; Cornillet-Lefebvre P; Ifrah N; Leverger G; Dombret H; Boissel N; Haferlach T; Preudhomme C
Blood; 2018 Jul; 132(2):187-196. PubMed ID: 29692343
[TBL] [Abstract][Full Text] [Related]
18. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
20. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
